Key terms
About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EXEL news
Today
6:26am ET
Buy Rating Affirmed for Exelixis Amid Solid Revenue and Strategic Growth Initiatives
Yesterday
8:18am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Atricure (ATRC) and Glaukos (GKOS)
Yesterday
2:18am ET
Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress
May 01
11:11am ET
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Exelixis (EXEL) and Merit Medical Systems (MMSI)
May 01
9:05am ET
Exelixis (EXEL) Receives a Buy from Bank of America Securities
May 01
7:37am ET
Exelixis price target raised to $27 from $25 at TD Cowen
May 01
6:42am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)
May 01
6:17am ET
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
May 01
6:14am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
May 01
3:50am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)
May 01
12:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Apr 30
4:07pm ET
Exelixis reports Q1 EPS 17c, consensus 24c
Apr 30
6:53am ET
Biotech Sector: M&A Fuels Renewed Excitement
Apr 11
4:42am ET
Exelixis downgraded to Equal Weight from Overweight at Barclays
Apr 10
12:25am ET
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
Apr 08
10:10pm ET
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
Mar 29
4:33pm ET
Jacqueline Wright to Exit Exelixis Board in 2024
Mar 21
6:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Mar 11
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
12:20am ET
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
Feb 27
7:01pm ET
Exelixis exec Haley sells 47,020 common shares
Feb 26
3:11pm ET
Fly Insider: Exelixis, Akami among week’s notable insider trades
Feb 26
3:11pm ET
Fly Insider: Exelixis, Akami among week’s notable insider trades
Feb 26
7:17am ET
Truist Financial Keeps Their Buy Rating on Exelixis (EXEL)
Feb 23
7:48am ET
Maintaining Buy Rating on Exelixis Amid Patent Litigation and Strong Growth Prospects
Feb 16
6:27am ET
5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024
Feb 12
8:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
Feb 11
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Envista Holdings (NVST)
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
7:50am ET
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)
Feb 08
1:02am ET
A New Cause for Concern: Exelixis Adds a New Environmental / Social Risk
No recent press releases are available for EXEL
EXEL Financials
Key terms
Ad Feedback
EXEL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EXEL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
